-
Mashup Score: 0Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut - 6 month(s) ago
Key Points. Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL.Adverse events oc
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Fixed-Duration, Triple-Combination Therapy Shows Efficacy for Patients With High-Risk CLL | ASH Clinical News | American Society of Hematology - 7 month(s) ago
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. The triple combination of obinutuzumab, ibrutinib, and venetoclax has shown a relatively high response rate among previously untreated patients with high-risk chronic lymphocytic leukemia (CLL), according to study results published in Blood. The limited-duration triple combination therapy achieved a complete response of 58.5% in the phase II CLL2-GIVe trial of 41 patients with high-risk CLL. Most adverse events
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In previously untreated patients with high-risk chronic lymphocytic #leukemia #CLL, a limited-duration combo therapy of #obinutuzumab, #ibrutinib, and #venetoclax achieved a complete response of 58.5% in the phase II CLL2-GIVe trial. https://t.co/jQRGGBe5v6
-
-
Mashup Score: 18How to Treat Chronic Lymphocytic Leukemia (CLL) with Dr. Jeff Sharman – ONC Brothers - 7 month(s) ago
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and…
Source: oncbrothers.comCategories: Latest Headlines, Partners & KOLsTweet-
w/@jeff_sharman we🗣️SoC for #CLL & key📝 to 🔍 in the community: - Fixed⏰Rx vs. BTKi - #Obinutuzumab/#Rituximab - #Venetoclax management Full discussion: - https://t.co/YuEQBXnZHX - Also on the “Oncology Brothers” podcast #Leusm #HemeTwitter #MedTwitter #OncTwitter https://t.co/n76iML2HOm
-
-
Mashup Score: 0Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study - 8 month(s) ago
Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Dr. Christopher Flowers, of @MDAndersonNews, showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining #zanubrutinib with #obinutuzumab vs obinutuzumab monotherapy. #lymsm https://t.co/1Jm6TYq5F3
-
-
Mashup Score: 0CLL Treatment: Managing Adverse Events With Venetoclax and Obinutuzumab - 11 month(s) ago
John Allan, MD, an expert on chronic lymphocytic leukemia, details adverse events seen with venetoclax and obinutuzumab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
John Allan, MD, discusses some of the AEs seen with venetoclax & #obinutuzumab. @WeillCornell https://t.co/Qpas00WLX7
-
-
Mashup Score: 0
Adult patients with chronic lymphocytic leukemia had significantly better minimal residual disease and progression-free survival results when treated with venetoclax and obinutuzumab or venetoclax, obinutuzumab, and ibrutinib vs standard chemoimmunotherapy
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ventoclax + #obinutuzumab with or without #ibrutinib was superior compared with chemoimmunotherapy as first-line treatment in patients with previously untreated, advanced #CLL. #leusm https://t.co/rRq0VRYFz7
-
-
Mashup Score: 0CLL Treatment: Managing Adverse Events With Venetoclax and Obinutuzumab - 12 month(s) ago
John Allan, MD, an expert on chronic lymphocytic leukemia, details adverse events seen with venetoclax and obinutuzumab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
John Allan, MD, an expert on chronic lymphocytic #leukemia, details adverse events seen with #venetoclax and #obinutuzumab. #CLL #leusm | @WeillCornell https://t.co/bp8nECF6Z2
-
-
Mashup Score: 0
Melanie Goldfarb, MD, MSc, FACS, FACE, discusses the current treatment landscape for patients with thyroid cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An expert on chronic lymphocytic #leukemia reviews the CLL14 trial, evaluating #venetoclax plus #obinutuzumab in patients with previously untreated #CLL. #leusm | @WeillCornell https://t.co/q8rcs4RqOI
-
-
Mashup Score: 0
An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An overview of the CLL14 trial which assessed #venetoclax plus #obinutuzumab in patients with previously untreated #CLL. #lymsm | @WeillCornell https://t.co/39gFxqHa6m
-
-
Mashup Score: 0‘Superior’ CLL regimen cuts chemo in half - 2 year(s) ago
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall survival rates that compare favorably with six-cycle regimens.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
‘Superior’ #CLL regimen cuts chemo in half👇 https://t.co/kGzwUZ7MzF @MDedgeHemOnc #Ibrutinib #Obinutuzumab https://t.co/NcNm6h9pDr
-
Final analysis of the #CLL2-GIVe trial: #obinutuzumab, #ibrutinib, and #venetoclax for untreated CLL with del(17p)/TP53mut 👉https://t.co/xKxTqFowPs @Blood @UniklinikUlm🇩🇪| #Multicenter https://t.co/nKHcjFeGkg